Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock.

Other analysts have also recently issued research reports about the company. TD Cowen reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Benchmark increased their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $4.59 on Tuesday. The stock has a market cap of $577.70 million, a PE ratio of -3.43 and a beta of 1.32. Humacyte has a 1 year low of $2.80 and a 1 year high of $9.97. The firm has a fifty day moving average price of $4.52 and a 200-day moving average price of $5.64.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, November 8th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same period in the prior year, the company earned ($0.25) EPS. On average, research analysts expect that Humacyte will post -1.27 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock valued at $6,606,799 in the last three months. Corporate insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently made changes to their positions in HUMA. Brookstone Capital Management purchased a new position in shares of Humacyte during the fourth quarter valued at approximately $56,000. ACT Wealth Management LLC purchased a new position in Humacyte during the 4th quarter valued at $57,000. Concurrent Investment Advisors LLC bought a new position in Humacyte in the 3rd quarter valued at $75,000. FORA Capital LLC purchased a new stake in Humacyte in the third quarter worth $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte during the second quarter worth $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.